AI English summary of an SEC filing — figures as filed

The company said Alok Sonig notified it on November 5, 2025 that he will resign as Executive Vice President and Group President, Pharmaceuticals.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Nov 12, 2025Period of report Nov 5, 2025Summary published (UTC) Oct 16, 2026

Key points

AI summary

The company said Alok Sonig notified it on November 5, 2025 that he will resign as Executive Vice President and Group President, Pharmaceuticals.
Baxter International said Mr. Sonig's resignation will take effect on December 1, 2025.
The company said Mr. Sonig decided to resign to join another company in the healthcare industry.
The company said it filed the executive resignation under Form 8-K Item 5.02, signed on November 12, 2025.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Notice of Alok Sonig's Resignation

The company said Alok Sonig notified it on November 5, 2025 that he will resign as Executive Vice President and Group President, Pharmaceuticals.

Source · Based on the filing body and exhibits

Resignation Effective Date December 1, 2025

Baxter International said Mr. Sonig's resignation will take effect on December 1, 2025.

Source · Based on the filing body and exhibits

Reason for Resignation: Joining Healthcare Industry Company

The company said Mr. Sonig decided to resign to join another company in the healthcare industry.

Source · Based on the filing body and exhibits

Form 8-K Item 5.02 Disclosure

The company said it filed the executive resignation under Form 8-K Item 5.02, signed on November 12, 2025.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.